2018-02-14 06:07:38 UTC

VIDEO: Non-invasive Detection of Early- and Late-Stage PDAC

Specific patterns of volatile organic compounds (VOCs) in urine samples can identify patients with pancreatic ductal adenocarcinoma (PDAC), researchers report in the February issue of Gastroenterology. The noninvasive technology, based on ion mobility spectrometry, can be used to discriminate between healthy individuals vs individuals with early- or advanced-stage cancer.

A. Image of field asymmetric ion mobility spectroscopy output showing the plume of ion dispersion from a urine sample from a healthy individual (AU, arbitrary units). B. Plume of ion dispersion from a urine sample of a patient with PDAC.

VOCs are metabolic products of microbes that can be detected in urine, breath, and feces. Ramesh P. Arasaradnam et al investigated whether alterations in cell functions and microbes in patients with PDAC lead to altered patterns of VOCs that can be detected in urine specimens.

In a video, the authors describe their procedure. The authors collected urine samples from 81 patients with pancreatic cancer (different stages) and 81 healthy individuals. A 5 mL urine sample from each individual was added to special glass vial, leaving some air above the sample. The samples were placed in the ion mobility spectrometry unit and ion mobility was measured in the air above the samples (known as the headspace).

Once all the samples were analyzed, 4 different classifiers were applied to the data (sparse logistic regression, random forest, gaussian process classifier, and a support vector machine algorithm).

Arasaradnam et al report that this technology identified patients with PDAC with 91% sensitivity and 83% specificity, with an area under the curve value of 0.92, using the support vector machine algorithm.

The results were validated by randomly splitting the data into the training and test set, and produced similar results, with an AUC of 0.92, 90% sensitivity, and 81% specificity.

When the authors compared samples from patients with early-stage disease (I/II) vs healthy individuals, the analysis identified the samples with 91% sensitivity, 78% specificity, and an AUC of 0.89.

When they compared samples from patients with early-stage I/II vs late-stage disease (III/IV), the analysis identified the samples with 82% sensitivity and 89% specificity, with an AUC of 0.92, again using a support vector machine algorithm.

Arasaradnam et al say that the advantages of this test are that it requires only a 5-mL urine sample, and it is more rapid and more cost-effective than other gas analysis technologies. The technology provide an exciting new approach to identify biomarkers of early-stage PDAC and provide earlier treatment.

More on Pancreatic Cancer

Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine

Feb. 28, 2018

With its incidence approaching mortality, and with 300,000 new cases diagnosed worldwide in 2013, PDAC is currently the fourth leading cause of cancer-related death and predicted to become the second by 2030

Blog: Non-Invasive Detection of Early- and Late-Stage PDAC

Feb. 14, 2018

Researchers report that urine samples can identify patients with pancreatic ductal adenocarcinoma (PDAC). Read more on the AGA Journals Blog.

Exome-Wide Association Study of Pancreatic Cancer Risk

Feb. 1, 2018

The authors conducted the first case-control exome-wide association study to identify inherited coding variation that affects pancreatic cancer risk.